04:55 AM EDT, 09/14/2026 (MT Newswires) -- Cellectis (ALCLS.PA) said Monday it plans to focus on becoming an in vivo gene editing company after a strategic review. The move, approved by the board on Sept. 11, is expected to extend the company's cash runway into the second half of 2028 and support the development of Cellectis' in vivo gene editing pipeline, including its Heal-101 and Heal-201 programs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.